http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Tue, 14 Aug 2018 18:18:00 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Result of AGM ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726152250_13733152/ Thu, 26 Jul 2018 15:22:50 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726152250_13733152/ <![CDATA[RNS press release - AGM Statement ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726070022_13731777/ Thu, 26 Jul 2018 07:00:22 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726070022_13731777/ <![CDATA[RNS press release - Final Patient Recruited in STEM Phase IIa Trial ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180725070005_13729973/ Wed, 25 Jul 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180725070005_13729973/ <![CDATA[RNS press release - Grant of share options, issue of equity and TVR ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180710110003_13712146/ Tue, 10 Jul 2018 11:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180710110003_13712146/ <![CDATA[RNS press release - Posting of Annual Report and AGM Notice ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180621123003_13688939/ Thu, 21 Jun 2018 12:30:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180621123003_13688939/ <![CDATA[RNS press release - Full Year Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180613070006_13677202/ Wed, 13 Jun 2018 07:00:06 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180613070006_13677202/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090530_13674198/ Mon, 11 Jun 2018 09:05:30 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090530_13674198/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090022_13674180/ Mon, 11 Jun 2018 09:00:22 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090022_13674180/ <![CDATA[RNS press release - Interim Update on STEM Trial ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611070003_13673651/ Mon, 11 Jun 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611070003_13673651/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607164031_13671646/ Thu, 07 Jun 2018 16:40:31 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607164031_13671646/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607163514_13671638/ Thu, 07 Jun 2018 16:35:14 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607163514_13671638/ <![CDATA[RNS press release - Notification of Preliminary Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180530070010_13658960/ Wed, 30 May 2018 07:00:10 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180530070010_13658960/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180515110024_13641614/ Tue, 15 May 2018 11:00:24 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180515110024_13641614/ <![CDATA[RNS press release - Upcoming Investor Presentations ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180514070011_13639038/ Mon, 14 May 2018 07:00:11 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180514070011_13639038/ <![CDATA[RNS press release - Grant of further European patent ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180502070013_13626601/ Wed, 02 May 2018 07:00:13 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180502070013_13626601/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180426164020_13620662/ Thu, 26 Apr 2018 16:40:20 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180426164020_13620662/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180426163533_13620649/ Thu, 26 Apr 2018 16:35:33 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180426163533_13620649/ <![CDATA[RNS press release - Presentation at World Orphan Drug Congress USA ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180424070002_13615390/ Tue, 24 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180424070002_13615390/ <![CDATA[RNS press release - Research Collaboration with Imperial College ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180320070003_13572824/ Tue, 20 Mar 2018 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180320070003_13572824/ <![CDATA[RNS press release - Update on Novel Sulforaphane Analogues ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180305070006_13553809/ Mon, 05 Mar 2018 07:00:06 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180305070006_13553809/ <![CDATA[RNS press release - Poster Presentation of SFX-01 Mechanistic Data ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180115070004_13495582/ Mon, 15 Jan 2018 07:00:04 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180115070004_13495582/ <![CDATA[RNS press release - Notification of Major Interest in Shares ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180110163154_13492104/ Wed, 10 Jan 2018 16:31:54 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180110163154_13492104/ <![CDATA[RNS press release - Notification of Major Interest in Shares ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180105094910_13486807/ Fri, 05 Jan 2018 09:49:10 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180105094910_13486807/ <![CDATA[RNS press release - Notification of Major Interest in Shares ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180105094837_13486806/ Fri, 05 Jan 2018 09:48:37 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180105094837_13486806/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180102174453_13482928/ Tue, 02 Jan 2018 17:44:53 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180102174453_13482928/ <![CDATA[RNS press release - Result of General Meeting ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171228114935_13479208/ Thu, 28 Dec 2017 11:49:35 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171228114935_13479208/ <![CDATA[RNS press release - Grant of Options ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171222101019_13475923/ Fri, 22 Dec 2017 10:10:19 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171222101019_13475923/ <![CDATA[RNS press release - Collaboration with King's College London ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171213070003_13463209/ Wed, 13 Dec 2017 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171213070003_13463209/ <![CDATA[RNS press release - Hardman Res.: Funded to the end of Phase II trials ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171211071501_13460343/ Mon, 11 Dec 2017 07:15:01 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171211071501_13460343/ <![CDATA[News - Evgen Pharma raises £2.3mln to fund its two clinical trials ]]> http://www.proactiveinvestors.co.uk/companies/news/188497/evgen-pharma-raises-23mln-to-fund-its-two-clinical-trials-188497.html Evgen Pharma plc (LON:EVG) has applied a meaty discount to its shares in order to get its £2.3mln fundraiser away.

Investors who took part in the placing received new paper at 12p. The stock, which closed at 17p on Thursday after opening at 20.5p, was changing hands for around 27p in October and almost 30p in February.

READ: Evgen Pharma and the power of plants for potential drug breakthrough

The proceeds from the share sale will be used to progress two phase II clinical trials involving patients with subarachnoid haemorrhage (a type of stroke) and metastatic breast cancer.

The company in its half-yearly update said it is making “exciting progress” with the studies and will be reporting data next year.

READ: Evgen Pharma shares jump after positive updates on two Phase II clinical trials for its SFX-01 treatment

“The additional funds will provide valuable working capital as we drive forward our pioneering work in sulforaphane-based therapeutics," said chief executive Steve Franklin.

]]>
Fri, 08 Dec 2017 07:48:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188497/evgen-pharma-raises-23mln-to-fund-its-two-clinical-trials-188497.html
<![CDATA[RNS press release - Placing and Notice of General Meeting ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171208071501_13458766/ Fri, 08 Dec 2017 07:15:01 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171208071501_13458766/ <![CDATA[RNS press release - Interim Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171208070003_13458415/ Fri, 08 Dec 2017 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171208070003_13458415/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171123110548_13441984/ Thu, 23 Nov 2017 11:05:48 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171123110548_13441984/ <![CDATA[RNS press release - Price Monitoring Extension ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171123110034_13441975/ Thu, 23 Nov 2017 11:00:34 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171123110034_13441975/ <![CDATA[RNS press release - First European Patent Grant ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171004070005_13385022/ Wed, 04 Oct 2017 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20171004070005_13385022/ <![CDATA[RNS press release - Issue of Equity and Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170831070005_13346513/ Thu, 31 Aug 2017 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170831070005_13346513/ <![CDATA[RNS press release - SFX-01 data published in Peer Reviewed Journal ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170802130001_13317017/ Wed, 02 Aug 2017 13:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170802130001_13317017/ <![CDATA[RNS press release - AGM Statement ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170726070003_13307366/ Wed, 26 Jul 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170726070003_13307366/ <![CDATA[RNS press release - Charity-funded Study of SFX-01 in TNBC ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170711123001_13291097/ Tue, 11 Jul 2017 12:30:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170711123001_13291097/ <![CDATA[RNS press release - Posting of Annual Report and AGM Notice ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170621100001_13268129/ Wed, 21 Jun 2017 10:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170621100001_13268129/ <![CDATA[RNS press release - Hardman Research: Making clinical progress ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170621071501_13267784/ Wed, 21 Jun 2017 07:15:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170621071501_13267784/ <![CDATA[RNS press release - Full Year Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170613070004_13257903/ Tue, 13 Jun 2017 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170613070004_13257903/ <![CDATA[News - Evgen Pharma shares jump after positive updates on two Phase II clinical trials for its SFX-01 treatment ]]> http://www.proactiveinvestors.co.uk/companies/news/178638/evgen-pharma-shares-jump-after-positive-updates-on-two-phase-ii-clinical-trials-for-its-sfx-01-treatment-178638.html Evgen Pharma PLC (LON:EVG) saw its shares jump almost 12% higher this morning after the drug development company reported positive updates on two Phase II clinical trials for its SFX-01 treatment with “no safety or tolerance issues reported to date”.

In a statement, the AIM-listed group said the first patient dosed in its STEM clinical study, testing SFX-01 in the treatment and evaluation of metastatic breast is now approaching week 24 – having been treated in January – and has demonstrated “no disease progression for three consecutive scans. “

On this basis, Evgen said it has initiated a “compassionate use programme”, so that patients can continue to receive SFX-01 after week 24.

It added that STEM will now recruit 60 patients from multiple sites in the UK and from sites in up to four other European countries. 

The firm added, due to protracted regulatory submissions in France, Spain and the Czech Republic, it is now projecting the final read-out from the STEM study in the second half of calendar year 2018.

Second SAS trial site initiated at Queen Elizabeth Hospital in Birmingham

In SAS, the other Phase II trial using SFX-01 for subarachnoid haemorrhage treatment, Evgen said that  to date 34 patients have been recruited at the Southampton site, with the first dosed in May 2016, and it will recruit a total of 90 patients. 

The group noted that, in its second meeting since the start of the SAS trial, the independent Data Safety Monitoring Board also confirmed there are no safety issues attributable to SFX-01.

The company also announced that a second SAS trial site has been initiated at Queen Elizabeth Hospital in Birmingham to accelerate patient recruitment.

Evgen said it  is anticipating read-out from the SAS study around the end of calendar year 2018.

Encouraged by requirement to initiate a compassionate use programme

Dr Stephen Franklin, Evgen Pharma’s CEO said: "We are very pleased that there have been no safety or tolerance issues reported to date on either of our two Phase II trials and we are delighted to have successfully initiated a second site for the SAS trial.

“In the STEM trial, we will provide the market with an interim data analysis in the first half of calendar year 2018 and we are encouraged by the requirement to initiate a compassionate use programme."

In mid-morning trading, Evgen shares were up 11.7%, or 2.25p at 21.5p.

In a note to clients, broker Northland Capital said: “Positive news for Evgen Pharma with the Company making significant progress, despite a minor delay, in both of its phase two trails.

“There have been no safety issues or tolerance issues for either of the Phase II trials to date and final read-outs from both the studies are expected next year, a major milestone for the Company.”

]]>
Thu, 01 Jun 2017 10:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/178638/evgen-pharma-shares-jump-after-positive-updates-on-two-phase-ii-clinical-trials-for-its-sfx-01-treatment-178638.html
<![CDATA[RNS press release - Compassionate Use Programme and Trials Update ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170601070004_13244889/ Thu, 01 Jun 2017 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170601070004_13244889/ <![CDATA[RNS press release - Notice of Preliminary Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170525070013_13237860/ Thu, 25 May 2017 07:00:13 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20170525070013_13237860/ <![CDATA[News - Evgen Pharma soars on news of US patent grant ]]> http://www.proactiveinvestors.co.uk/companies/news/173144/evgen-pharma-soars-on-news-of-us-patent-grant-173144.html Shares in Evgen Pharma plc (LON:EVG) soared on Tuesday afternoon after the drug developer revealed it had been granted a US patent which “significantly broadens and extends [its] intellectual property” around its lead product SFX-01.

Shares were up 14% to 25p shortly before the close of play in London.

The new patent covers the manufacturing process of SFX-01 – a synthetic version of the naturally occurring compound sulforaphane – and runs until 2033.

“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market and is the first of a potentially broad geographical spread of patents that are pending in Europe, Japan, India, China, Canada, Brazil and Australia,” said chief executive Stephen Franklin.

Under the terms of the licence agreement with PharmAgra Labs Inc – the US lab which invented the compound – Evgen holds the exclusive worldwide rights to the patent.

Evgen is currently conducting two phase II trials of SFX-01; one in advanced breast cancer and the other in a type of stroke called subarachnoid haemorrhage.

Today’s patent grant comes a day after Evgen signed a services agreement with a consortium of Cheshire-based drug development firms.

The group aims to help clients turn promising molecules and compounds into valued medicines, which Evgen hopes to do with SFX-01.

]]>
Tue, 14 Feb 2017 15:56:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/173144/evgen-pharma-soars-on-news-of-us-patent-grant-173144.html
<![CDATA[RNS press release - Half Yearly Report ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161205070017_013055569/ Mon, 05 Dec 2016 07:00:17 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161205070017_013055569/ <![CDATA[RNS press release - Notice of Interim Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161117070014_013037874/ Thu, 17 Nov 2016 07:00:14 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161117070014_013037874/ <![CDATA[RNS press release - Grant of Options ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161101123003_013020146/ Tue, 01 Nov 2016 12:30:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20161101123003_013020146/ <![CDATA[RNS press release - Update re SFX-01 Data at ECTRIMS 2016 ]]> http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20160915070009_012966560/ Thu, 15 Sep 2016 07:00:09 +0100 http://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20160915070009_012966560/